Centessa (CNTA) Files Form 3 Showing Accardi’s Initial 216k-Share Stake
Rhea-AI Filing Summary
Centessa Pharmaceuticals plc (CNTA) – Form 3 Initial Statement of Beneficial Ownership
The filing discloses that Mario Alberto Accardi, President of the company’s Orexin Program, beneficially owns 216,485 ordinary shares, including 25,150 restricted share units. All holdings are reported as direct.
Accardi also holds a series of employee share options covering a total of 323,425 ordinary shares with exercise prices ranging from $3.85 to $16.90 and expirations between 2032-2035. The options vest monthly over four-year periods or upon performance goal achievement, starting on various dates from March 2022 through March 2025.
No transactions were reported; this Form 3 simply establishes the insider’s starting ownership position as of 13 June 2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine Form 3 lists insider’s 216.5k shares and 323.4k options; no purchases or sales, minimal market impact.
This filing is an administrative disclosure required when an individual becomes a Section 16 insider. It confirms Mario Accardi’s equity stake—roughly 216k shares (plus RSUs) and sizeable options—aligning his incentives with shareholders. There is no indication of open-market activity or material corporate events; therefore, the disclosure is informational rather than catalytic. Investors gain clarity on insider alignment but should not expect immediate price movement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Includes 25,150 Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments with the first installment vesting on March 1, 2022. Represents the vested portion of such option granted on February 1, 2022 that vests upon the achievement of applicable performance goals. 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023. 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024. 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
